Pfizer Inc. (PFE) Stock

Pfizer Inc. (PFE) is a Healthcare stock trading at $25.22 (as of 2026-06-18), with a market capitalization of $149.21B and a trailing P/E of 20.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Valuation — source: SEC EDGAR (first-party)
Price$25.22
Market Cap$149.21B
P/E Ratio20.0
EV / EBITDA14.6
Price / Book1.65
Price / Sales2.36
DCF Value (model)$10.98
DCF Upside vs Price-56.5%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$62.58B
Net Margin12.4%
Return on Equity8.3%
Debt / Equity0.71
Current Ratio1.25
Revenue Growth (YoY)5.4%
EPS Growth (YoY)-9.6%
FCF Growth (YoY)23.0%
Financial Health — source: SEC EDGAR
Altman Z-Score1.93 (grey)
Piotroski F-Score5/9 (moderate)
Valuation vs Sector & Industry
Stock P/E20.0
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-4.6%
vs Industry15.8%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($13.99B)
Institutional Holders Tracked10
Congressional Trades (recent)10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOAlbert Bourla
Employees81,000
CountryUS
IPO Date1972-06-01

Related Companies (Business model: Big Pharma / Branded Drugs; 8 closest by market cap; US-domiciled)

  • Johnson & Johnson (JNJ)
  • AbbVie Inc. (ABBV)
  • Merck & Co., Inc. (MRK)
  • Abbott Laboratories (ABT)
  • Amgen Inc. (AMGN)
  • Gilead Sciences, Inc. (GILD)
  • Bristol-Myers Squibb Company (BMY)
  • Regeneron Pharmaceuticals, Inc. (REGN)
PFE earnings history · PFE institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.